share_log

Cantor Fitzgerald Maintains Overweight on Oncternal Therapeutics, Lowers Price Target to $1.3

Benzinga ·  Apr 4, 2023 07:34

Cantor Fitzgerald analyst Li Watsek maintains Oncternal Therapeutics (NASDAQ:ONCT) with a Overweight and lowers the price target from $4 to $1.3.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment